Harvard Bioscience (HBIO) Rejects Skystone Buyout Offer
More News related to HBIO
- Harvard Bioscience (HBIO) Posts Q3 EPS of $0.04, Down Y/Y
- HBIO Reports Third Quarter 2009 Revenue Growth of 5% Over Third Quarter 2008
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Harvard Bioscience, Inc. Schedules Third Quarter 2009 Conference Call for November 4, 2009
- Harvard Bioscience (HBIO) Appoints McNaughton New CFO
More News related to Corporate News
- Mexican Restaurants (CASA) Posts Q3 Loss of $0.07, Better Y/Y; Revs Down
- Cosi (COSI) Posts Q3 Loss of $0.06, Beats By 2c
- Enterprise GP Holdings (EPE) Posts Q3 EPS of $0.18, Misses Views
- Mindray Medical (MR) Tops Q3 EPS by 6c; Revs Light
- Neenah Paper (NP) Tops Q3 Views
Harvard Bioscience (Nasdaq: HBIO) today announced that its Board of Directors unanimously rejected an unsolicited buyout offer from Skystone Advisors LLC to acquire all outstanding shares of the Company's common stock for $5.00 per share.
Harvard Bioscience, Inc. develops, distributes, manufactures, and markets apparatus and scientific instruments used in life science research at pharmaceutical and biotechnology companies, universities, and government laboratories worldwide.
Related Categories
Corporate NewsMergers and Acquisitions
Stocks Mentioned
+0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
